Treatment Guide

TMS Treatment for Depression: How It Works and What Trials Show

TMS treatment for depression: 58% of 307 U.S. clinic patients responded and 37% remitted (2012). Sessions, eligibility, side effects, durability, coverage.

Mental Health Stats Research Team 8 min read

Key Takeaways

  • TMS treatment for depression delivers magnetic pulses to the left prefrontal cortex, usually in daily sessions 5 days a week for 4 to 6 weeks[1].4 to 6 weeks[1]
  • Across 42 U.S. TMS practices, 58.0% of 307 outpatients met clinician-rated response criteria and 37.1% reached remission by the end of acute treatment[2].58.0%[2]
  • A 2019 BMJ network meta-analysis of 113 trials and 6,750 patients found standard high-frequency left rTMS was associated with higher odds of response than sham (odds ratio 3.17)[3].OR 3.17[3]
  • In a 414-patient Lancet trial, a 3-minute theta burst session was non-inferior to a 37.5-minute standard session, and headache was the most common side effect in both groups (64% and 65%)[4].3 min[4]
  • Among people who responded to a first TMS course, 46.3% still met response criteria 12 months later in a 2019 meta-analysis[5].46.3%[5]
  • Eligibility rules differ: the 2022 VA/DoD guideline suggests rTMS after 2 or more failed medication trials[6], while one Medicare contractor requires severe depression and at least 1 failed or poorly tolerated medication[7].2+ trials[6]
How to read these numbers: Response usually means a drop of 50% or more on a depression rating scale, and remission means a score low enough to count as minimal symptoms; the exact cutoffs differ by study[8]. Blinded, sham-controlled trials report lower figures than open-label or clinic studies: in one NIH-sponsored trial, 14.1% remitted on blinded active TMS, while almost 30% remitted in the open-label phase[9].

What Is TMS Treatment for Depression?

TMS treatment for depression is a noninvasive procedure in which an electromagnetic coil held against the scalp sends repeated magnetic pulses into the brain, inducing weak electrical currents that stimulate nerve cells[1]. For depression, the coil targets the left prefrontal cortex, a region involved in mood regulation[1].

It is used mainly when depression has not improved with antidepressants, the pattern described on the treatment-resistant depression page, which reports how often standard treatment falls short. The underlying diagnosis is covered under major depressive disorder.

The FDA cleared the first rTMS device for depression in 2008, for people who had not responded to at least one antidepressant in the current episode[1]. Clearances have since extended to obsessive-compulsive disorder, migraine, short-term smoking cessation and depression with anxious distress[10].

The repeated-pulse form is called repetitive TMS, or rTMS, and that is what clinics mean by TMS therapy for depression. The magnetic field is about as strong as an MRI scanner's, but it switches on and off very rapidly[1].

Repetitive transcranial magnetic stimulation (rTMS)

A noninvasive therapy that uses an electromagnet to stimulate the brain with repeated low-intensity pulses; the rapidly switching magnetic field induces weak electrical currents that activate neurons and neural circuits[1].

Related Terms

TMS therapy
theta burst stimulation (iTBS)
deep TMS
Stanford neuromodulation therapy (SNT)
motor threshold

Source: National Institute of Mental Health

How a TMS Course Works: Sessions, Schedule and Sensation

A standard course runs 5 days a week for 4 to 6 weeks, with each session lasting 3 to 40 minutes depending on the protocol[1]. Treatment is outpatient and needs no anesthesia or sedation, and patients can drive to and from appointments[10].

The first visit includes motor-threshold mapping: the operator moves the coil over the scalp to find each person's threshold, which sets the treatment site and dose[10]. During stimulation, most people feel a knocking or tapping on the head[1].

Standard rTMS vs. theta burst

The original high-frequency protocol delivers 3,000 pulses at 10 Hz over 37.5 minutes[9]. Intermittent theta burst stimulation (iTBS) compresses a session into about 3 minutes[4].

The THREE-D trial randomized 414 adults with treatment-resistant depression at three Canadian university hospitals to one protocol or the other[4]. Scores on the 17-item Hamilton scale fell from 23.5 to 13.4 with 10 Hz rTMS and from 23.6 to 13.4 with iTBS, meeting the trial's test for non-inferiority[4].

Accelerated and deep TMS

Accelerated protocols deliver several sessions a day with short breaks and often finish within a week[1]. Stanford neuromodulation therapy (SNT), formerly called SAINT, gives 10 iTBS sessions a day for 5 consecutive days, aimed with functional MRI at an individually chosen spot in the left prefrontal cortex[8].

Deep TMS may use two coils to deliver more stimulation and reach larger structures deeper in the brain[1].

Who Qualifies for TMS Therapy?

Guidelines place TMS after medication, not before it. The 2022 VA/DoD depression guideline suggests offering rTMS to patients with partial or no response to two or more adequate medication trials, graded as a weak recommendation in favor[6].

The original 2008 FDA clearance required failure of at least one antidepressant[1]. Insurers often set a higher bar: the American Psychiatric Association notes that many carriers cover standard TMS after 3 to 4 unsuccessful antidepressant trials[10].

Age limits apply too. In March 2024 the FDA cleared rTMS as an add-on treatment for depression in adolescents 15 and older, and it is not approved below that age[1].

Who is not a candidate

Metal implants in the head are the main exclusion; the APA lists aneurysm clips or coils, cochlear implants, cardiac defibrillators and a history of epilepsy as reasons a person would not be a candidate[10]. One Medicare contractor treats magnetic-sensitive implants within 30 cm of the coil as an absolute contraindication, and seizure history or psychotic symptoms in the current episode as relative ones[7].

What Is the Success Rate of TMS for Depression?

The success rate of TMS for depression depends on the protocol, the patients and whether the study used a sham control. The broadest comparison, a 2019 BMJ network meta-analysis, pooled 113 trials with 6,750 adults in a major depressive episode[3].

Compared with sham, standard high-frequency left rTMS was associated with higher odds of response (odds ratio 3.17), as were iTBS (3.20) and bilateral rTMS (4.92)[3]. Every stimulation approach was at least as acceptable as sham when measured by dropout[3]. The authors rated 83% of trials as low or unclear risk of bias and noted that the precision of estimates varied considerably[3].

Blinded trials show smaller absolute numbers. In a 2010 NIH-sponsored trial of 199 antidepressant-free outpatients, 14.1% remitted with active rTMS versus 5.1% with sham[9].

Routine-practice data run higher. Across 42 U.S. practices treating 307 outpatients whose depression persisted despite medication, clinician-rated response was 58.0% and remission 37.1%[2]. Self-reported response ranged from 41.5% to 56.4% depending on the questionnaire[2].

The APA summarizes the evidence as roughly one in two patients responding and one in three reaching remission[10].

The highest figures come from accelerated SNT. In a 29-person sham-controlled trial, 78.6% of the active group met remission criteria at some point in the 4 weeks after treatment, compared with 13.3% on sham[8]. Results were reported at a planned interim analysis, and the authors called for further trials on durability and comparisons with other treatments[8].

TMS for Depression: Key Study Results

StudyDesignPatientsKey result
Mutz et al., BMJ 2019Network meta-analysis, 113 trials6,750HF left rTMS vs. sham: OR 3.17 for response
George et al., 2010Sham-controlled RCT, drug-free patients199Remission 14.1% active vs. 5.1% sham
Blumberger et al., Lancet 2018iTBS vs. 10 Hz rTMS (THREE-D)414HRSD-17 fell to 13.4 in both groups
Carpenter et al., 201242 U.S. practices, observational307Response 58.0%; remission 37.1%
Cole et al., AJP 2022Accelerated SNT vs. sham29Remission 78.6% vs. 13.3%
Senova et al., 2019Durability meta-analysis, 19 studies24746.3% of responders still responding at 12 months

Selected outcomes from studies of TMS for depression; designs, populations and outcome definitions differ by study[3][9][4][2][8][5].

1OR = odds ratio. HRSD-17 = 17-item Hamilton Rating Scale for Depression; lower scores mean fewer symptoms.

2Patients for Senova et al. is the 12-month analysis sample. Open-label and clinic results are not directly comparable with sham-controlled results.

Sources

  • •BMJ, 2019
  • •Archives of General Psychiatry, 2010
  • •The Lancet, 2018
  • •Depression and Anxiety, 2012
  • •American Journal of Psychiatry, 2022
  • •Brain Stimulation, 2019
Clinician-rated response to TMS among 307 U.S. outpatients treated in routine practice
58.0%

Remission was 37.1% in the same group. The study had no sham arm, so it describes real-world outcomes rather than the effect beyond placebo.

"Clinician-assessed response rate (CGI-S) was 58.0% and remission rate was 37.1%."

Depression and Anxiety(2012) View Source

TMS Side Effects and Safety

The most common side effects are discomfort where the coil sits, tingling or contraction of scalp, jaw or face muscles, mild headache and brief lightheadedness or dizziness[1].

Headache is frequent. In THREE-D, 64% of the 10 Hz group and 65% of the iTBS group reported headache during treatment[4]. Pain ratings averaged 3.8 out of 10 for iTBS and 3.4 for 10 Hz rTMS, and dropout was 8% and 6%[4].

Serious events are uncommon. The APA lists severe headache, fainting, hearing loss (prevented with earplugs) and seizure, which it puts at about 1 in 10,000[10]. NIMH notes that long-term side effects have not been determined[1].

In the accelerated SNT trial, no severe adverse events occurred, and fatigue was the most common side effect in both the active and sham groups[8].

TMS vs. ECT and Antidepressants

Electroconvulsive therapy is still considered the gold standard for treatment-resistant depression, and NIMH states that rTMS does not match its therapeutic effects[1]. In the BMJ network analysis, bitemporal ECT had the highest odds of response versus sham (odds ratio 8.91), and bitemporal and high-dose right unilateral ECT were associated with higher response than other active treatments[3].

TMS trades some efficacy for a lighter procedure: no anesthesia, stimulation targeted to one site rather than generalized, and treatment in an office setting[1]. The APA lists no known cognitive side effects[10]. How ECT is given and what its memory risks are is covered in electric shock therapy (ECT).

TMS is usually added to antidepressant medication rather than replacing it[10]. It has also been tested alone; the 2010 sham-controlled trial enrolled only patients who were off antidepressants[9].

For the same patient group, the VA/DoD guideline also suggests ketamine or esketamine as augmentation after several failed medication trials[6]. Those options are covered in infusion therapy, and standard drug classes in anti-depression meds.

How Long Do TMS Results Last?

A 2019 meta-analysis of 19 studies followed people who responded to an initial TMS course[5]. Of those initial responders, 66.5% still met response criteria at 3 months, 52.9% at 6 months and 46.3% at 12 months[5].

The 12-month estimate rests on 9 studies and 247 patients, a thinner base than the short-term figures[5]. Receiving maintenance treatment, and a higher share of women in a study, predicted higher sustained response at specific time points[5].

Durability of accelerated protocols is less established; the SNT authors listed it as a question for future trials[8].

Does Insurance or Medicare Cover TMS?

Coverage is usually tied to documented medication failure. The APA reports that many health insurers cover standard TMS once 3 to 4 antidepressant trials have not worked[10].

Medicare decides TMS coverage regionally through local coverage determinations. Novitas policy L34998 covers TMS for up to six weeks in adults with severe major depressive disorder who failed or could not tolerate at least one medication, when a psychiatrist who examined the patient face to face orders it[7]. The same policy does not cover moderate depression or OCD[7].

Across the policies cited here, the number of failed medication trials named ranges from one to four[7][6][10]. How many Americans take antidepressants in the first place is tracked in antidepressant usage statistics.

Frequently Asked Questions

Sources & References

  1. National Institute of Mental Health. Brain Stimulation Therapies. National Institutes of Health. Published 2024. Accessed October 2026. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies [Link]
  2. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety. Published 2012. Accessed October 2026. https://onlinelibrary.wiley.com/doi/10.1002/da.21969 [Link]
  3. Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. Published 2019. Accessed October 2026. https://www.bmj.com/content/364/bmj.l1079 [Link]
  4. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet. Published 2018. Accessed October 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30295-2/abstract [Link]
  5. Senova S, Cotovio G, Pascual-Leone A, Oliveira-Maia AJ. Durability of antidepressant response to repetitive transcranial magnetic stimulation: systematic review and meta-analysis. Brain Stimulation. Published 2019. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/30344109/ [Link]
  6. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. U.S. Department of Veterans Affairs. Published 2022. Accessed October 2026. https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPG_ProviderSummary_Final_508_updated.pdf [Link]
  7. Novitas Solutions. Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive Disorder (L34998). Centers for Medicare & Medicaid Services. Published 2022. Accessed October 2026. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=34998 [Link]
  8. Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. American Journal of Psychiatry. Published 2022. Accessed October 2026. https://psychiatryonline.org/doi/10.1176/appi.ajp.2021.20101429 [Link]
  9. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Archives of General Psychiatry. Published 2010. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/20439832/ [Link]
  10. American Psychiatric Association. What is Transcranial Magnetic Stimulation (TMS)? American Psychiatric Association. Published 2026. Accessed October 2026. https://www.psychiatry.org/patients-families/what-is-tms [Link]